Answers are grounded in this paper and cite their sources.
Our study demonstrates a shift in migraine medication utilization from 2017-2020, where increased use of CGRP mABs had a significant contribution to increased costs. These increased pharmacy costs must be weighed against the improved tolerability of these agents likely resulting in other healthcare and indirect cost savings.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: